NCT06669429View on ClinicalTrials.gov

A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

August 30, 2025

Conditions
Dyslipidemia
Interventions
DRUG

RS-C1001

Subjects will receive RS-C1001 tablets orally as a single ascending dose

DRUG

RS-C1001

Subjects will receive RS-C1001 tablets orally as a multiple ascending dose

DRUG

RS-C1001

Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast

DRUG

placebo

Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose

DRUG

placebo

Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose

DRUG

Placebo

Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER